Dyadic International, Inc. , a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced that the expansion of its research laboratory in The Netherlands is now complete.
Dyadic's chief operating officer, Danai Brooks, stated, "Commercial interest in Dyadic's C1 expression technology has increased with new end markets, such as biopharmaceuticals, and new customers, such as BASF. By investing in our R&D capabilities, we are able to expand our new product development pipeline, take on additional projects with our strategic partners, and invest in strengthening the technology platform. We are extremely excited about several new projects commencing in 2014 and we expect to provide additional details about these projects in the coming weeks."
